Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v2.4.0.8
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 7,279 $ 11,029
Marketable securities, current 58,390 59,819
Collaboration receivable 18,094 15,635
Prepaid expenses and other current assets 2,246 1,167
Total current assets 86,009 87,650
Marketable securities, non-current 16,364  
Property and equipment, net 686 812
Other assets 1,059 1,059
Total assets 104,118 89,521
Current liabilities:    
Accounts payable 1,689 908
Accrued clinical and development expenses 7,444 5,750
Accrued liabilities 3,161 2,257
Deferred revenue, current 14,722 8,536
Total current liabilities 27,016 17,451
Warrant liability 23,421 32,558
Deferred revenue, non-current 76,916 53,097
Deferred rent 240 268
Total liabilities 127,593 103,374
Commitments and contingencies (Note 7)      
Stockholders' equity (deficit):    
Preferred stock, $0.001 par value: Authorized: 2,000,000 shares; no shares issued and outstanding.      
Common stock, $0.001 par value: Authorized: 150,000,000 shares at December 31, 2013 and 2012; Issued and outstanding: 59,232,611 and 56,431,207 shares at December 31, 2013 and 2012, respectively. 59 56
Additional paid-in capital 328,116 309,343
Accumulated other comprehensive (loss) income 28 11
Accumulated deficit (351,678) (323,263)
Total stockholders' equity (deficit) (23,475) (13,853)
Total liabilities and stockholders' equity (deficit) $ 104,118 $ 89,521